The Meningitis Vaccine Project

Vaccine

Volumn 25, Issue SUPPL. 1, 2007, Pages

  LaForce, F Marc ^a   Konde, Kader ^b   Viviani, Simonetta ^a   Préziosi, Marie Pierre ^b  

^a PATH   (France)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Meningococcal conjugate vaccine; Meningococcal meningitis; Public private partnerships

Indexed keywords

CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; MENINGITIS VACCINE; MENINGOCOCCUS VACCINE; POLYSACCHARIDE TETANUS TOXOID VACCINE; POLYSACCHARIDE VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; VACCINE;

AFRICA; ARTICLE; CONJUGATION; DEVELOPING COUNTRY; DISEASE CONTROL; DRUG COST; DRUG FORMULATION; DRUG SAFETY; EPIDEMIC; EUROPE; FERMENTATION; FINANCIAL MANAGEMENT; HERD IMMUNITY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INDIA; MASS IMMUNIZATION; MENINGITIS; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PATHOGENESIS; PRIORITY JOURNAL; PUBLIC HEALTH; VACCINE PRODUCTION; WORLD HEALTH ORGANIZATION;

AFRICA; HUMANS; MASS IMMUNIZATION; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; VACCINES, CONJUGATE; WORLD HEALTH ORGANIZATION;

EID: 34547673284     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.04.049     Document Type: Article

References (17)

1. Lapeyssonie L. La méningite cérébrospinale en Afrique. Bull World Health Organ 28 Suppl (1963) 3-114
2. Greenwood B., Manson, and Lecture. Meningococcal meningitis in Africa [published version & manuscript version in file]. Trans R Soc Trop Med Hyg 93 (1999) 341-353
3. Meningitis stockpile for Africa. Wkly Epidemiol Rec 2002;77:430-1.
4. Group A and C meningococcal vaccines [WHO position paper, 1999]. Wkly Epidemiol Rec 1999;74:297-303.
5. WHO. Control of epidemic meningococccal disease. WHO practical guidelines (WHO/EMC/BAC/98. 3) [Lutte contre les épidémies de méningite à méningocoque. Guide pratique OMS, 2ème édition] vol. i (1998), World Health Organization, Geneva p. 1-x, 83
6. Reingold A.L., Broome C.V., Hightower A.W., Ajello G.W., Bolan G.A., Adamsbaum C., et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 2 (1985) 114-118
7. Hassan-King M.K., Wall R.A., and Greenwood B.M. Meningococcal carriage, meningococcal disease and vaccination. J Infect 16 (1988) 55-59
8. Schneerson R., Barrera O., Sutton A., and Robbins J.B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 152 (1980) 361-376
9. Watt JP, Levine OS, Santosham M. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22-25, 2002. J Pediatr 2003;143:S163-87.
10. Miller E., Salisbury D., and Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 Suppl 1 (2001) S58-S67
11. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., and Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364 (2004) 365-367
12. Maiden M.C., and Stuart J.M. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359 (2002) 1829-1831
13. Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., and Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326 (2003) 365-366
14. WHO. Joint recommendations for the development and introduction of conjugate vaccines against meningococcal disease in the African and Eastern Mediterranean Regions, April 2000.
15. Jodar L., LaForce F.M., Ceccarini C., Aguado T., and Granoff D.M. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 361 (2003) 1902-1904
16. Kshirsagar N., Mur N., Thatte U., Gogtay N., Viviani S., Preziosi M.P., et al. Safety and immunogenicity of a new meningococcal Group A conjugate vaccine in healthy adults. Vaccine (2007) (this supplement)
17. Soriano-Gabarro M., Rosenstein N., and LaForce F.M. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project. J Health Popul Nutr 22 (2004) 275-285